

Update tot 30-04-2020

1. **Treatment for emerging viruses: Convalescent plasma and COVID-19.** Brown BL, McCullough J. *Transfusion and Apheresis Science*. 2020.
2. **Potential of live pathogen vaccines for defeating the COVID-19 pandemic: history and mechanism.** Chen JW, Chen JM. *J Med Virol*. 2020. <http://dx.doi.org/10.1002/jmv.25920>.
3. **Points to consider in the preparation and transfusion of COVID-19 convalescent plasma.** Epstein J, Burnouf T. *Vox Sang*. 2020. <http://dx.doi.org/10.1111/vox.12939>.
4. **Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy.** Franchini M, Marano G, Velati C, Pati I, Pupella S, Liunbruno GM. *Vox Sang*. 2020. <http://dx.doi.org/10.1111/vox.12940>.
5. **The post-lockdown period should be used to acquire effective therapies for future resurgence in SARS-Cov-2 infections.** Krause KL, Furneaux R, Benjes P, Brimble M, Davidson T, Denny W, et al. *The New Zealand medical journal*. 2020;133(1513):107-11.
6. **A short review on antibody therapy for COVID-19.** Kumar GV, Jeyanthi V, Ramakrishnan S. *New microbes and new infections*. 2020:100682. <http://dx.doi.org/10.1016/j.nmni.2020.100682>.
7. **Convalescent (Immune) Plasma Therapy with All Aspects: Yesterday, Today and COVID-19.** Özdemir Ö, Melek Arsoy HE. *ERCÝYES MEDICAL JOURNAL*. 2020;42(3).
8. **Convalescent Plasma, an Apheresis Research Project Targeting and Motivating the Fully Recovered COVID 19 Patients: A Rousing Message of Clinical Benefit To Both Donors and Recipients Alike.** Seghatchian J, Lanza F. *Transfusion and Apheresis Science*. 2020.
9. **Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic.** Sullivan HC, Roback JD. *Transfusion Medicine Reviews*. 2020.
10. **Current status of potential therapeutic candidates for the COVID-19 crisis.** Zhang J, Xie B, Hashimoto K. *Brain, behavior, and immunity*. 2020. <http://dx.doi.org/10.1016/j.bbi.2020.04.046>.
11. **Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19.** Zhang L, Pang R, Xue X, Bao J, Ye S, Dai Y, et al. *Aging*. 2020;12. <http://dx.doi.org/10.18632/aging.103102>.

Literatuuroverzicht tot 23-04-2020

1. **Searching for a coronavirus cure in the blood.** C&EN Global Enterprise. 2020.
2. **Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea.** Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, et al. Journal of Korean medical science. 2020;35(14):e149. <http://dx.doi.org/10.3346/jkms.2020.35.e149>.
3. **Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19.** Alzoughool F, Alanagreh L. The International journal of risk & safety in medicine. 2020. <http://dx.doi.org/10.3233/JRS-201017>.
4. **Critical care management of adults with community-acquired severe respiratory viral infection.** Arabi YM, Fowler R, Hayden FG. Intensive Care Medicine. 2020.
5. **Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Plasma using a Coronavirus Antigen Microarray.** Assis RRd, Jain A, Nakajima R, Jasinskas A, Felgner J, Obiero JM, et al. bioRxiv. 2020:2020.04.15.043364.
6. **Deployment of convalescent plasma for the prevention and treatment of COVID-19.** Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. The Journal of clinical investigation. 2020. <http://dx.doi.org/10.1172/JCI138745>.
7. **Blood transfusion during the COVID-19 outbreak.** Cai X, Ren M, Chen F, Li L, Lei H, Wang X. Blood Transfus. 2020;18(2):79-82.
8. **The convalescent sera option for containing COVID-19.** Casadevall A, Pirofski LA. Journal of Clinical Investigation. 2020;130(4):1545-8.
9. **Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility.** Chan JFW, Zhang AJ, Yuan S, Poon VKM, Chan CCS, Lee ACY, et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020.
10. **[Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies].** Chen C, Zhang XR, Ju ZY, He WF. Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns. 2020;36:E005. <http://dx.doi.org/10.3760/cma.j.cn501120-20200224-00088>.
11. **Convalescent plasma as a potential therapy for COVID-19.** Chen L, Xiong J, Bao L, Shi Y. The Lancet Infectious Diseases. 2020;20(4):398-400.
12. **Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19.** Chen WH, Hotez PJ, Bottazzi ME. Human vaccines & immunotherapeutics. 2020:1-4. <http://dx.doi.org/10.1080/21645515.2020.1740560>.
13. **Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.** Choy K-T, Yin-Lam Wong A, Kaewpreedee P, Sia S-F, Chen D, Yan Hui KP, et al. Antiviral Research. 2020.
14. **Therapeutic Drug Monitoring of Dalbavancin Treatment in Severe Necrotizing Fasciitis in 3 Critically Ill Patients: A Grand Round.** Corona A, Agarossi A, Veronese A, Cattaneo D, Avolio A. Therapeutic Drug Monitoring. 2020.
15. **COVID-19: A Review of Therapeutics Under Investigation.** Crosby JC, Heimann MA, Burluson SL, Anzalone BC, Swanson JF, Wallace DW, et al. Journal of the American College of Emergency Physicians Open. 2020.

16. **Treatment of COVID-19: Old tricks for new challenges.** Cunningham AC, Goh HP, Koh D. *Critical Care*. 2020;24(1).
17. **Emergence of a Novel Coronavirus (COVID-19): Protocol for Extending Surveillance Used by the Royal College of General Practitioners Research and Surveillance Centre and Public Health England.** de Lusignan S, Lopez Bernal J, Zambon M, Akinyemi O, Amirthalingam G, Andrews N, et al. *JMIR public health and surveillance*. 2020;6(2):e18606. <http://dx.doi.org/10.2196/18606>.
18. **Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.** de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, et al. *Proc Natl Acad Sci U S A*. 2020;117(12):6771-6.
19. **Effectiveness of convalescent plasma therapy in severe COVID-19 patients.** Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. *Proc Natl Acad Sci U S A*. 2020. <http://dx.doi.org/10.1073/pnas.2004168117>.
20. **The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study.** Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. *medRxiv*. 2020:2020.03.16.20036145.
21. **Inactivation of three emerging viruses - severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus - in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light.** Eickmann M, Gravemann U, Handke W, Tolksdorf F, Reichenberg S, Mueller TH, et al. *Vox Sanguinis*. 2020.
22. **Convalescent Plasma Therapy for Covid-19: State of the Art.** Focosi D, Tang J, Anderson A, Tuccori M. 2020.
23. **Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).** Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. *JAMA cardiology*. 2020.
24. **The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak- A n update on the status.** Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. *Military Medical Research*. 2020;7(1).
25. **COVID-19 in a patient with long-term use of glucocorticoids: A study of a familial cluster.** Han Y, Jiang M, Xia D, He L, Lv X, Liao X, et al. *Clinical Immunology*. 2020;214.
26. **Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome.** Hendren NS, Drazner MH, Bozkurt B, Cooper LT, Jr. *Circulation*. 2020. <http://dx.doi.org/10.1161/CIRCULATIONAHA.120.047349>.
27. **USE OF CONVALESCENCE PLASMA IN THE TREATMENT OF PATIENTS INFECTED WITH COVID-19 VIRUS INFECTION (SARS-CoV-2).** Hindawi S. 2020.
28. **SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.** Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. *Cell*. 2020;181(2):271-80.e8.
29. **Effectiveness and Feasibility of Convalescent Blood Transfusion to Reduce COVID-19 Fatality Ratio.** Huo X, Sun X, Bragazzi NL, Wu J. Available at SSRN 3573611. 2020.
30. **Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?** Jawhara S. *International Journal of Molecular Sciences*. 2020.
31. **Pharmacologic Treatments and Supportive Care for Middle East Respiratory Syndrome.** Kain T, Lindsay PJ, Adhikari NKJ, Arabi YM, Van Kerkhove MD, Fowler RA. *Emerging infectious diseases*. 2020;26(6).

32. **A novel treatment approach to the novel coronavirus: An argument for the use of therapeutic plasma exchange for fulminant COVID-19.** Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. *Critical Care*. 2020;24(1).
33. **COVID-19 convalescent plasma transfusion.** Langhi DM, Santis GCD, Bordin JO. *Hematology, Transfusion and Cell Therapy*. 2020.
34. **Emergent Serum Therapy and Antibody Medicine to Counteract Sudden Attacks of COVID-19 and Other Pathogenic Epidemics.** Law PK. *Journal*. 2020(Issue).
35. **Coronavirus-associated bronchiolitis in an immunocompetent adult with anti-glomerular basement membrane disease.** Leung C, McCormack G. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*. 2019;3(2):117-20.
36. **[Potential antiviral therapeutics for 2019 Novel Coronavirus].** Li H, Wang YM, Xu JY, Cao B. *Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases*. 2020;43(3):170-2. <http://dx.doi.org/10.3760/cma.j.issn.1001-0939.2020.03.004>.
37. **[The keypoints in treatment of the critical coronavirus disease 2019 patient].** Li XY, Du B, Wang YS, Kang HYJ, Wang F, Sun B, et al. *Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases*. 2020;43:E026. <http://dx.doi.org/10.3760/cma.j.cn112147-20200224-00159>.
38. **Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients.** Ling Y, Xu S-B, Lin Y-X, Tian D, Zhu Z-Q, Dai F-H, et al. *Chinese Medical Journal*. 2020.
39. **Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19.** Ma J, Xia P, Zhou Y, Liu Z, Zhou X, Wang J, et al. *Clinical Immunology*. 2020;214.
40. **[The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19].** Ma W-X, Ran X-W. *Sichuan da xue xue bao Yi xue ban = Journal of Sichuan University Medical science edition*. 2020;51(2):146-50.
41. **Middle East respiratory syndrome.** Memish ZA, Perlman S, Van Kerkhove MD, Zumla A. *The Lancet*. 2020;395(10229):1063-77.
42. **Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.** Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. *Emerg Microbes Infect*. 2020;9(1):757-60.
43. **Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes.** Monteiro WM, Brito-Sousa JD, Baía-da-Silva D, Melo GCd, Siqueira AM, Val F, et al. *Rev Soc Bras Med Trop*. 2020;53:e20200155-e.
44. **Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.** Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. *Emerging Microbes and Infections*. 2020;9(1):680-6.
45. **Effect of isolation practice on the transmission of middle east respiratory syndrome coronavirus among hemodialysis patients: A 2-year prospective cohort study.** Park HC, Lee S-H, Kim J, Kim DH, Cho A, Jeon HJ, et al. *Medicine (Baltimore)*. 2020;99(3):e18782-e.
46. **Convalescent Plasma to Treat COVID-19: Chinese Strategy and Experiences.** Pei S, Yuan X, Zhimin Zhang Z, Run Yao R, Xie Y, Minxue Shen M, et al. *medRxiv*. 2020:2020.04.07.20056440.
47. **Management and Treatment of COVID-19: The Chinese Experience.** Peng F, Tu L, Yang Y, Hu P, Wang R, Hu Q, et al. *Canadian Journal of Cardiology*. 2020.

48. **Potent neutralizing antibodies in the sera of convalescent COVID-19 patients are directed against conserved linear epitopes on the SARS-CoV-2 spike protein.** Poh CM, Carissimo G, Wang B, Amrun SN, Lee CY-P, Chee RS-L, et al. *bioRxiv*. 2020:2020.03.30.015461.
49. **Management challenges for chronic dysimmune neuropathies during the COVID-19 pandemic.** Rajabally YA, Goedee HS, Attarian S, Hartung HP. *Muscle Nerve*. 2020. <http://dx.doi.org/10.1002/mus.26896>.
50. **Convalescent Plasma to Treat COVID-19: Possibilities and Challenges.** Roback JD, Guarner J. *JAMA - Journal of the American Medical Association*. 2020:E1-E2.
51. **Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma.** Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. *JAMA - Journal of the American Medical Association*. 2020.
52. **Successful treatment of plasma exchange followed by intravenous immunoglobulin in a critically ill patient with 2019 novel coronavirus infection.** Shi H, Zhou C, He P, Huang S, Duan Y, Wang X, et al. *International journal of antimicrobial agents*. 2020:105974. <http://dx.doi.org/10.1016/j.ijantimicag.2020.105974>.
53. **Hospital pharmacists' pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience.** Song Z, Hu Y, Zheng S, Yang L, Zhao R. *Research in social & administrative pharmacy : RSAP*. 2020. <http://dx.doi.org/10.1016/j.sapharm.2020.03.027>.
54. **COVID-19: Herd Immunity and Convalescent Plasma Transfer Therapy.** Syal K. *J Med Virol*. 2020. <http://dx.doi.org/10.1002/jmv.25870>.
55. **Covid-19: FDA approves use of convalescent plasma to treat critically ill patients.** Tanne JH. *BMJ (Clinical research ed)*. 2020;368:m1256.
56. **Convalescent plasma: A possible treatment of COVID-19 in India.** Teixeira da Silva JA. *Medical journal, Armed Forces India*. 2020. <http://dx.doi.org/10.1016/j.mjafi.2020.04.006>.
57. **Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how.** Tiberghien P, de Lambalerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. *Vox Sang*. 2020. <http://dx.doi.org/10.1111/vox.12926>.
58. **Therapeutic Management of COVID-19 Patients: A systematic review.** Tobaigy M, Qashqary M, Al-Dahery S, Mujallad A, Hershman AA, Kamal MA, et al. *Infection Prevention in Practice*. 2020.
59. **Clinical features and treatment of COVID-19 patients in northeast Chongqing.** Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. *J med virol*. 2020.
60. **The Potential for Antibody-Dependent Enhancement of SARS-CoV-2 Infection: Translational Implications for Vaccine Development.** Wang J, Zand MS. *Journal of Clinical and Translational Science*. 2020.
61. **Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China.** Wang Z, Yang B, Li Q, Wen L, Zhang R. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
62. **Pivotal Role of Convalescent Plasma in Managing Emerging Infectious Diseases.** Wong HK, Lee CK. *Vox Sanguinis*. 2020.
63. **Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.** Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, et al. *Cell Res*. 2020;30(4):343-55.

64. **Insight into 2019 novel coronavirus - an updated interim review and lessons from SARS-CoV and MERS-CoV.** Xie M, Chen Q. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020.
65. **Biological Product Development Strategies for Prevention and Treatment of Coronavirus Disease 2019.** Yan CX, Li J, Shen X, Luo L, Li Y, Li MY. Sichuan da xue xue bao Yi xue ban = Journal of Sichuan University Medical science edition. 2020;51(2):139-45.
66. **Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.** Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. J Med Virol. 2020. <http://dx.doi.org/10.1002/jmv.25882>.
67. **Convalescent Plasma Therapy for Corona Virus Disease 2019: a Long Way to Go but Worth Trying.** Yoo JH. Journal of Korean medical science. 2020;35(14):e150. <http://dx.doi.org/10.3346/jkms.2020.35.e150>.
68. **Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for the COVID-19 outbreak.** Yu B, Jin C, Zhang J, Wu H, Zhou X, Yao H, et al. Journal. 2020(Issue).
69. **The epidemiology, diagnosis and treatment of COVID-19.** Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. International journal of antimicrobial agents. 2020.
70. **Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection.** Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, et al. Chest. 2020.
71. **Potential interventions for novel coronavirus in China: A systematic review.** Zhang L, Liu Y. Journal of Medical Virology. 2020;92(5):479-90.
72. **Clinical trial analysis of 2019-nCoV therapy registered in China.** Zhang Q, Wang Y, Qi C, Shen L, Li J. Journal of Medical Virology. 2020.
73. **First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab.** Zhang X, Song K, Tong F, Fei M, Guo H, Lu Z, et al. Blood Adv. 2020;4(7):1307-10.
74. **Challenges of Convalescent Plasma Therapy on COVID-19.** Zhao Q, He Y. Journal of Clinical Virology. 2020;127.
75. **Development and validation of a S1 protein-based ELISA for the specific detection of antibodies against equine coronavirus.** Zhao S, Smits C, Schuurman N, Barnum S, Pusterla N, Van Kuppeveld F, et al. Viruses. 2019;11(12).
76. **Coronavirus disease 2019 (COVID-19): a clinical update.** Zhou M, Zhang X, Qu J. Frontiers of medicine. 2020.
77. **Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia.** Zhu H, Wang L, Fang C, Peng S, Zhang L, Chang G, et al. Translational Pediatrics. 2020;9(1):51-60.